Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and/or anti‐ interleukin ‐17 treatment: A real‐life 52‐week retrospective study

2020 ◽  
Author(s):  
Angelo Ruggiero ◽  
Gabriella Fabbrocini ◽  
Eleonora Cinelli ◽  
Matteo Megna
Keyword(s):  
Retrospective Study ◽  
Real Life ◽  
Interleukin 17 ◽  
Efficacy And Safety

Real-life efficacy and safety of ingenol mebutate for the treatment of actinic keratosis of the face and scalp: A single arm retrospective study

2016 ◽  
Vol 27 (6) ◽  
pp. 525-530 ◽  
Author(s):  
Francesco Ricci ◽  
Sara Tambone ◽  
Luca Neri ◽  
Luca Fania ◽  
Antonella Piccioni ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Actinic Keratosis ◽  
Real Life ◽  
Efficacy And Safety ◽  
Ingenol Mebutate ◽  
The Face

scholarly journals Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study

2020 ◽  
Vol 2020 ◽  
pp. 1-3
Author(s):  
Clémentine Carlet ◽  
Damien Bichard ◽  
Marie Aleth Richard ◽  
Emmanuel Mahé ◽  
Clémence Saillard ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Critical Role ◽  
Real Life ◽  
Solid Cancer ◽  
Infliximab Treatment ◽  
Efficacy And Safety ◽  
Drug Survival ◽  
The Mean

Background. Although infliximab (IFX) has been available since 2005, there are very little data on the long-term drug survival of infliximab in real-life. Objective. Our aim was to identify and describe psoriasis patients treated with IFX for longer than 6 years. Methods. Psoriasis patients treated with IFX for longer than 6 years were retrospectively included. Demographic and clinical data were collected in May 2018. Results. Between January 2005 and December 2012, 43 patients were maintained on IFX for 6 years or longer. IFX was introduced as a 4.5 line of systemic therapy. The mean duration of IFX treatment was 8.5 years (6–12). In May 2018, 30 patients (70%) were still maintained on IFX at 4–6 mg/kg every 8–10 weeks with an efficiency of about 100%. IFX was stopped in 13 patients (30%) mainly for loss of efficacy in 6 patients (46%). Three patients developed solid cancer including bladder cancer, lung cancer, and prostate cancer. Limitation. Retrospective study. Conclusion. We report the efficacy and safety of IFX maintained for up to 12 years in psoriasis patients. The long-term use of IFX was associated with a high BMI confirming the critical role of weight-based dosing for this drug.

Efficacy and safety of long-acting pasireotide in acromegalic patients in the real life: The reappraisal of the first-dose follow-up visit

2020 ◽  
Author(s):  
Claudio Urbani ◽  
Francesca Dassie ◽  
Benedetta Zampetti ◽  
Di Certo Agostino Maria ◽  
Renato Cozzi ◽  
...  
Keyword(s):  
Real Life ◽  
Efficacy And Safety ◽  
The Real ◽  
Long Acting
Sign in / Sign up

Export Citation Format

Share Document